[{"address1": "20 North Audley Street", "city": "London", "zip": "W1K 6LX", "country": "United Kingdom", "phone": "44 20 7788 7414", "website": "https://viraxbiolabs.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 11, "companyOfficers": [{"maxAge": 1, "name": "Mr. James  Foster", "age": 38, "title": "Chairman & CEO", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 347500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason D. Davis", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 237500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark James Ternouth", "age": 55, "title": "Chief Technical Officer & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 90000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nigel  McCracken M.Sc., Ph.D.", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joel  Yeung", "title": "Accounting Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Clement  Monteil", "title": "Head of Scientific Research & Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Wang", "title": "Head of Procurement & Sourcing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lily  Fu", "title": "Head of Supply Chain", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.97, "open": 1.81, "dayLow": 1.69, "dayHigh": 2.11, "regularMarketPreviousClose": 1.97, "regularMarketOpen": 1.81, "regularMarketDayLow": 1.69, "regularMarketDayHigh": 2.11, "forwardPE": -1.0368421, "volume": 2501275, "regularMarketVolume": 2501275, "averageVolume": 1378622, "averageVolume10days": 8546630, "averageDailyVolume10Day": 8546630, "bid": 1.65, "ask": 1.99, "bidSize": 100, "askSize": 100, "marketCap": 4652943, "fiftyTwoWeekLow": 0.6, "fiftyTwoWeekHigh": 5.45, "priceToSalesTrailing12Months": 58.674454, "fiftyDayAverage": 0.8294, "twoHundredDayAverage": 1.70155, "currency": "USD", "enterpriseValue": -1681954, "floatShares": 1326120, "sharesOutstanding": 2361900, "sharesShort": 600, "sharesShortPriorMonth": 11994, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.00029999999, "heldPercentInsiders": 0.26795998, "heldPercentInstitutions": 0.0076200003, "shortRatio": 0.02, "shortPercentOfFloat": 0.00029999999, "impliedSharesOutstanding": 2361900, "bookValue": 3.496, "priceToBook": 0.5635011, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -6923535, "trailingEps": -17.7, "forwardEps": -1.9, "lastSplitFactor": "1:10", "lastSplitDate": 1702857600, "enterpriseToRevenue": -21.21, "52WeekChange": -0.5075, "SandP52WeekChange": 0.23232913, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VRAX", "underlyingSymbol": "VRAX", "shortName": "Virax Biolabs Group Limited", "longName": "Virax Biolabs Group Limited", "firstTradeDateEpochUtc": 1658410200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "4a944c5c-f1d1-3041-8c4c-e4a3baeb60d2", "messageBoardId": "finmb_1685878340", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.97, "targetHighPrice": 20.0, "targetLowPrice": 20.0, "targetMeanPrice": 20.0, "targetMedianPrice": 20.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 5205443, "totalCashPerShare": 2.873, "totalDebt": 181706, "quickRatio": 6.847, "currentRatio": 7.587, "totalRevenue": 79301, "debtToEquity": 2.976, "revenuePerShare": 0.044, "returnOnAssets": -0.70984, "returnOnEquity": -1.34826, "freeCashflow": -4103304, "operatingCashflow": -5340931, "revenueGrowth": 12.281, "grossMargins": 0.113929994, "operatingMargins": -35.37548, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-10"}]